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ABSTRACT
Incretins are metabolic hormones released after a meal that
increase insulin secretion from pancreatic β-cells. The two
main incretins are the intestinal peptides glucagon-like pep-
tide-1 and glucose-dependent insulinotropic polypeptide.
Both induce a decrease in glycemia, slow down the absorption
of nutrients, and are inactivated by the enzyme dipeptidyl
peptidase-4. Recently, incretin-based therapies have become
a useful tool to treat diabetic patients, and different studies
have focused on the identification of glucagon-like peptide-1
receptor agonists, including those of natural origin. This re-
view focuses on the new findings of medicinal plants and nat-
ural products as possible active agents on the potentiation of
incretin receptor signaling. Among these, soluble fiber from
species of Plantago and guar gum show promising effects, iri-
doid derivatives are relevant activators of incretin receptors,
and derivatives of cyanidin, especially diglycosylated ones,
are an interesting source of dipeptidyl peptidase-4 inhibitors.
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When glucose is administrated orally, the insulin secretion re-
sponse is two- to threefold higher than the response elicited by a
comparable intravenous glucose administration, a phenomenon
denominated “incretin effect”. Incretins are peptide hormones
that are rapidly released in the gut in response to food and, togeth-
er with an increase in blood glucose, stimulate insulin secretion [1–
5]. GIP and GLP-1 are the most representative incretin hormones
secreted by the upper (GIP, K cells) and lower (GLP-1, L cells) gut
[4, 5]. In the blood, GLP-1 can be found as two molecular forms
with equivalent effects, GLP-1(7-37) and GLP-1(7-36)amide, with
the latter being predominant in the blood after a meal [6].
In the fasted state, the GLP-1 circulating level is low, but in-
creases after eating (▶ Fig. 1A). However, both GLP-1 and GIP
have a short half-life, quickly decreasing due to enzymatic degra-1
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▶ Fig. 1 Incretins and their role in the organism. A Physiological
effects. B Role of DPP-4 on incretin functions. C Effects of DPP-4
inhibitors and GLP-1 receptor agonists on pancreatic cells.
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situation can be pharmacologically modified by employing two
approaches: (1) using DPP-4 inhibitors such as sitagliptin and
vildagliptin that preserve native GLP-1 or (2) with DPP-4-resistant
GLP-1 analogs (▶ Fig. 1C), such as exenatide and liraglutide,
among others [7, 8].
In the pathogenesis of T2D and in its initial stage, altered glu-
cose tolerance, experimental evidence shows a significant de-
crease in the incretin effect [9–11]. Interestingly, the insulino-
tropic and glucagonostatic effects of GLP-1 are well preserved in
T2D patients, and the pharmacological stimulation of GLP-1 re-
ceptors significantly improves glycemic control [4,6].
GLP-1 exerts several effects in different organs or systems.
Among them, it is important to mention the reduction in appetite
and food intake, thus leading to weight loss in the long term. This
fact, together with the key finding that GLP-1 secretion seems to
be impaired in obese subjects, suggests a pathogenic role in obe-
sity [4].
The effects of GIP and GLP-1 are related to the activation of
structurally different receptors associated with G proteins, lo-
cated in different organs, including the stomach, hypothalamus,
and endocrine pancreas [2,3, 12–14]. Activation of these recep-
tors on pancreatic β-cells increases cAMP and cytosolic Ca2+ levels,
which in turn increases insulin secretion in response to oral glu-
cose administration [3, 15]. Sustained activation of this pathway
leads to the activation of protein kinase A, gene expression, and
enhanced insulin synthesis, together with stimulation of β-cell
replication [16]. GLP-1 also inhibits glucagon secretion [2,17,
18]. An additional site of action has also been demonstrated for
GLP-1, which is the hepatoportal glucose “sensor” that is acti-
vated whenever a glucose gradient is established between the
portal region and the periphery as it occurs in the postprandial pe-
riod [19]. Glucose detection by the abovementioned sensor re-
quires not only a GLUT but also an activated GLP-1 receptor, in
turn establishing a gluco-incretin receptor system of physiological
relevance [19].
Additionally, GLP-1 inhibits gastric emptying and food inges-
tion, and enhances glucose disposal by neural mechanisms, con-
tributing to glucose homeostasis [20]. GIP and GLP-1 also have ef-
fects on adipose cells, bone, and the cardiovascular system. Re-
garding the latter, recent findings suggest that GLP-1 receptor
agonists, such as liraglutide, reduce cardiovascular events and
prolong life in high-risk patients with T2D [4].
Although the evidence is not complete, GLP-1 receptors have
also been identified in hepatocytes of rodents and humans [21,
22], and it has been postulated that their activation would directly
reduce hepatic steatosis in several experimental models [23,24].
These effects could be possibly mediated via activation of the in-
sulin signaling cascade [21] as well as the AMPK pathway [25]. In
this sense, Svegliati-Baroni et al. [22] showed that not only would
there be receptors for GLP-1 in human hepatocytes, but their
number would be decreased in patients with nonalcoholic steato-
hepatitis. Despite these evidences, other authors suggest that dif-
ferent peptides derived from the degradation of GLP-1 would act
through an independent pathway of the receptor, directly at the
mitochondrial level through the modulation of phosphorylation
and oxidative stress [26–28]. In addition, it has been shown that2
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cells both in vivo [29] and in vitro [30]. In summary, incretin hor-
mones have been proven to be key players in the pathophysiology
of obesity and T2D, and, in consequence, they have very high
therapeutic potential [31,32].
Several interesting approaches have been proposed for treat-
ing T2D, and these antidiabetic agents act with different or similar
mechanisms of action [33]. The use of biguanide and its deriva-
tives to treat diabetes can be traced back to the Middle Ages,
when administration of the aerial parts of Goatʼs Rue herb (Galega
officinalis L., Leguminosae) infusions was a common practice.
Galegin, isolated from this plant, became the main compound of
several from which metformin was synthesized [34]. These studies
continued until 1994, when the U.S. FDA approved metformin for
the treatment of T2D. This compound was shown to delay the
progression of T2D, reduce the risk of complications and mortality
by decreasing hepatic glucose synthesis from non-glycidic sub-
strates, and sensitize tissues to insulin. Since then, metformin has
been the first-choice oral drug in the treatment of T2D [35]. How-
ever, in circumstances where metformin is contraindicated or notRíos JL et al. Modulation of Diabetes… Planta Med 2019; 85: 1–15
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agonists and/or DPP-4 inhibitors are an option [8,36–38]. These
recently approved classes of therapeutic agents for the treatment
of T2D exert their actions through the potentiation of incretin re-
ceptor signaling or by expanding the half-life of GLP-1 [6].
In 2005, the FDA approved the first incretin mimetic, exena-
tide, originally isolated from the salivary secretions of the Gila
monster (Heloderma suspectum), a venomous lizard from the
western U.S.A. and Mexico [39]. Exenatide is a GLP-1 receptor
analogue resistant to DPP-4 degradation used as adjunctive ther-
apy for patients with T2D. Because GLP-1 analogues require injec-
tion, considerable effort has been devoted to creating an oral
agent able to target the incretin pathway. Inhibition of DPP-4 ex-
tends the half-life of native incretins, thereby prolonging their ef-
fects. In 2006, the FDA approved the first oral incretin enhancer,
sitagliptin, a selective DPP-4 inhibitor, for use as monotherapy or
in combination with metformin or thiazolidinedione [6]. Since
then, this new class of hypoglycemic agents is subject to continu-
ous evaluations of efficacy and safety [40–45].
In recent years, incretin-based therapies have become an im-
portant treatment option for patients with T2D. In order to im-
prove the various issues related to the efficacy and safety of these
drugs, the search for new drugs is necessary. Recently, studies
have focused on identifying non-peptidic agonists for the GLP-1
receptor [46,47]. For this reason, the aim of this review is to
present new findings of medicinal plants and natural products
that exert their actions through potentiation of incretin receptor
signaling.The Use of Food for the Control of Diabetes
through Incretin Increase
The main use of natural products for the control of glycemia was
through food. In the 1990s, different studies compared the ef-
fects of fatty acids on glucose, insulin, GIP, and GLP-1 levels. For
example, Thomsen et al. [48,49] studied the effect of olive oil,
comparing it with butter, on the levels of glucose, insulin, and
fatty acids, and demonstrated that this oil induced lower triacyl-
glycerol concentrations and higher HDL-cholesterol concentra-
tions than butter. No clear differences were observed in glycemia
or insulinemia, although higher concentrations of GLP-1 and GIP
were observed with the use of monounsaturated versus saturated
fatty acids, suggesting a relation between fatty acid composition,
incretin responses, and triacylglycerol postprandial metabolism in
patients with T2D [49]. In the same line, Iritani et al. [50] demon-
strated that oral triacylglycerols stimulated GLP-1 secretion in the
gut lumen and produced a second insulin peak at 4 h. These ef-
fects were corroborated by Prieto et al. [51] and by Cancelas et
al. [52], who observed that an olive oil-enriched diet increases
both GLP-1 release and the secretory response of insulin-produc-
ing cells to oral glucose administration, improving glucose toler-
ance in Wistar rats [51] and in an animal model of T2D (adult rats
injected with streptozotocin during the neonatal period) [52]. The
group of Professor Tso observed that incretins are in a higher con-
centration in intestinal lymph versus plasma [53,54] and, using a
lymph fistula rat model, they tested the dose-dependent relation-Ríos JL et al. Modulation of Diabetes… Planta Med 2019; 85: 1–15
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showing that the intraluminal lipid content was greater in GLP-1-
than in GIP-secreting cells [55]. In contrast, another study of inter-
est [56] demonstrated that the GLP-1 level and glycemia were not
affected by omega-3 fatty acid supplementation. In this study, the
researchers tested both fish oil (enriched in eicosapentaenoic acid
and docosahexaenoic acid) and flaxseed (Linum usitatissimum L.,
Linaceae) oil (enriched in α-linolenic acid) on Sprague-Dawley rats
for 7 weeks.
The incretin effect after lipid consumption in humans was
studied by Lindgren et al. [57] and Manning et al. [58]. Lindgrenʼs
group orally administered a lipid emulsion (Intralipid, 3mL/kg)
and observed an increase in total and intact GIP and GLP-1 levels.
However, when they administered the lipids i. v., no significant
modifications were detected, concluding that oral lipid ingestion
elicits a clear insulin response in association with increased GIP
and GLP-1 concentrations. To test the differences between cook-
ing with unheated sunflower (Helianthus annuus L., Compositae)
oil and thermally oxidized sunflower oil, Manning et al. [58] mea-
sured the plasma concentrations of GLP-1. There were no signifi-
cant differences in plasmatic GLP-1 concentrations while eating
either meals; however, the concentration was significantly in-
creased from 30min to a peak at 60min after the ingestion of an
unheated sunflower oil-cooked meal versus the thermally oxidized
sunflower oil-cooked meal.
Another edible plant, beets (Beta vulgaris L., Amaranthaceae),
was tested as a potential antidiabetic medicinal plant. Indeed,
the aqueous extract of B. vulgaris (whole plant) was the only active
fraction (50mg/kg) from a hydroethanolic extract fractioned with
solvents of different polarity. Administration of this extract at
different doses to T2D mice (db/db) significantly increased GLP-1
and enhanced insulin secretion, confirming the antihyperglycemic
activity of this plant [59].Medicinal Plant Products and Their Effect
on Incretin Secretion
Some researchers focus their studies on natural fractions from
medicinal plants. This is the case of Ellis et al. [60] and Gatenby
et al. [61], who have demonstrated that guar gum, at concentra-
tions found in the diet (20 or 40 g/kg), reduces glucose absorption
and insulin and GIP secretion during the postprandial period (4 h)
[60], and that 7.6 g of guar gum per meal attenuate insulinemia in
diabetic patients by increasing hepatic extraction of insulin [61].
More recently, den Besten et al. [62] demonstrated in both
humans and rodents that this beneficial effect of guar gum was
mediated by the short-chain fatty acids produced by colonic fer-
mentation. These short-chain fatty acids stimulate GLP-1 release,
increasing peripheral glucose clearance.
Another type of dietary fiber, soluble fiber from Plantago indica
L. (syn: Plantago psyllium L., Plantaginaceae) was studied by
Karhunen et al. [63] in humans obtaining similar results. Fiber-en-
riched meals decreased glycemia and insulinemia in healthy
young adults by strongly modifying postprandial signals arising
from the gastrointestinal tract. Postprandial GLP-1 concentrations
increased for 20min after the white wheat bread, low-fiber, and3
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ally toward the baseline. In contrast, the GLP-1 concentration after
the fiber and protein-rich meal decreased below the baseline for
the entire experimental period.
Other products with high interest are those containing phe-
nolic compounds, such as coffee and its main phenolic, chloro-
genic acid. It is largely known that dietary phenolics have positive
effects on the pattern of glucose uptake in the small intestine. In
this sense, Johnston et al. [64] observed the effects of caffeine and
chlorogenic acid from coffee on glycemia, insulinemia, and GIP
and GLP-1 secretion, modifying intestinal glucose absorption.
Other authors established that a supplement of chlorogenic acid
(e.g., as green decaffeinated coffee) lowers the glycemic index of
meals and increase GLP-1, reducing the risk for diabetes [65].
However, Esatbeyoglu et al. [66] studied different phenolic deriv-
atives from deep purple carrots [Daucus carota subsp. sativus
(Hoffm.) Arcang. var. atrorubens Alef., Apiaceae], such as the an-
thocyanin fraction, primarily phenolic acids and chlorogenic acid,
but none of them affected GLP-1 secretion and DPP-4 activity.
Overall, the phenolic fraction exhibited an inhibitory effect on α-
amylase and α-glucosidase activity and on cellular glucose uptake,
indicating potential antidiabetic properties.
Sweet potato [Ipomoea batatas (L.) Lam., Convolvulaceae]
leaves contain polyphenols such as caffeoylquinic acid derivatives.
Nagamine et al. [67] studied the effect of sweet potato leaf ex-
tract powder on hyperglycemia in type 2 diabetic mice and ob-
served that, after five weeks, the extract lowered glycemia. When
testing both the sweet potato leaf extract powder and its caffeoyl-
quinic acid derivatives in vitro, they found enhanced GLP-1 secre-
tion, demonstrating that the effect of sweet potato leaf extract
powder is mediated by the caffeoylquinic acid derivatives, which
attenuate postprandial hyperglycemia through the enhancement
of GLP-1.Potentiality of Medicinal Plants
as Incretin Modulators
Aside from food, medicinal plants have been used as a potential
source of antidiabetic agents, and many of them are of interest
as modulators of incretins. There are complete and good reviews,
such as the revision of Hung et al. [68] and Eddouks et al. [69], on
the discovery of plant-derived antidiabetic natural products,
which cover the years from 2005 to 2010 and until 2013, respec-
tively, but no references on incretins were included. However,
some articles describing this activity during this period were pub-
lished [60,61,70]. Ribnicky et al. [70] analyzed the effect of
Tarralin, an ethanolic extract of Russian tarragon (Artemisia dra-
cunculus L., Compositae), as a potential antihyperglycemic drug
in genetically diabetic KK‑Aγ mice and nondiabetic animals. Oral
administration of this extract (500mg/kg/d for 1 week) decreased
blood glucose levels by 24% in respect to the negative control,
whereas positive controls troglitazone (30mg/kg/d) and metfor-
min (300mg/kg/d) lowered glycemia by 28 and 41%, respectively.
Insulinemia was also reduced in diabetic mice by 33% with the ex-
tract, whereas its combination with troglitazone or metformin re-
duced it by 48 and 52%, respectively. The authors hypothesized a4
▪ Proof copy for correction only. All forms of publication, dup
Dear authors, please note that this pdf is compressed and only used for mail dipossible mechanism of action and what the active principles
would be, but these were not tested. Moreover, the extract de-
creased PEPCK mRNA expression in streptozotocin-induced dia-
betic rats, but PEPCK expression was not affected in nondiabetic
rats. In fact, it did not modify glycemia or insulinemia in nondia-
betic rats, but it did increase the binding of GLP-1 to its receptor
in vitro. For this reason, the authors proposed the potential use of
Tarralin as a supplement for the management of glycemia and in-
sulin resistance in diabetic patients [70]. Other authors, such as
the Park et al. [71], investigated the effects of different medicinal
plants used in Chinese medicine with interesting results; however,
they used mixtures of crude drugs and it is not easy to establish
the potentiality of each of them.
It is known that yerba mate (Ilex paraguariensis A.St.‑Hil., Aqui-
foliaceae) has antidiabetic properties [34]. In this sense, Hussein
et al. [72] investigated an aqueous extract of mate on diabetes
and metabolic syndrome effects in a mouse model. The extract
(50, 100mg/kg) was administered orally for 3 weeks and a signifi-
cant increase in GLP-1 was observed. Moreover, acute administra-
tion of the principal constituents of mate, dicaffeoyl quinic acids
and matesaponins, also produced a significant increase in GLP-1
levels, suggesting that yerba mate exerts anorexic effects by di-
rect induction of satiety and by stimulation of GLP-1 secretion, as
well as by modulating leptin levels. As mentioned earlier, these
same compounds, caffeoylquinic acid derivatives, were also de-
scribed as the active principles of sweet potato leaves [67].
Kubow et al. [73] tested a phenolic-rich potato (Solanum tu-
berosum L., Solanaceae) extract (final concentration: 1.93 or
3.5%, w/w) in C57BL/6 J mice with a high-fat diet for 10 weeks.
This extract attenuated weight gain by 63% in both male and fe-
male mice, an effect associated with a reduction in adiposity, but
sex differences were observed in GIP as well as other metabolic in-
dicators (insulin, ghrelin, leptin, and resistin). These differences
were not observed in other experiments with phenolics. Previ-
ously, Raasmaja et al. [74] demonstrated a decrease in circulating
GLP-1 in genetically obese Zucker rats fed with a high-fat/high-
cholesterol diet after the administration of a 70% ethanol extract
(obtained from a water extract) of Citrus maxima (Burm.) Merr.
[syn: Citrus grandis (L.) Osbeck, Rutaceae] at 300, 600, and
1200mg/kg, which could be related with an increase in glucagon
and glucose levels, as well as a decrease in the insulin level.
Bitter melon (Momordica charantia L., Cucurbitaceae) has been
reported as an antidiabetic fruit, but similar properties have also
been demonstrated for other parts of this plant [34]. Several me-
tabolites, such as α-eleostearic acid or a Zn-free protein, and
mechanisms have been described; however, the implication of
GLP-1 was not analyzed. In this way, Bhat et al. [75] recently
studied the effect of an aqueous extract (300mg/kg/d for 28 d)
of bitter melon on both normal and diabetic Wistar rats, demon-
strating that this extract increased insulinemia and GLP-1 in nor-
mal (nonsignificant) and in diabetic Wistar rats (significant,
p < 0.01). This effect was associated to elevated β-cell prolifera-
tion and insulin secretion.
The main medicinal plants and some of their relevant fractions
are compiled in ▶ Table 1, including plant material investigated,
extracts used, concentration, protocols employed, and effects ob-
tained in the experiments.Ríos JL et al. Modulation of Diabetes… Planta Med 2019; 85: 1–15
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▶ Table 1 Medicinal plants as incretin modulators.









Reduces glycemia and insulinemia,
and PEPCKmRNA expression
[70,71]
Citrus maxima Dried fruits 70% Ethanol extract obtained
from a water extract
300, 600, and 1200mg/kg
Genetically obese
Zucker rats
Decrease of circulating GLP-1 [74]












Guar gum 20 and 40mg/kg Human – diet Reduces glucose absorption,




Guar gum 7.6 g per meal Diabetic patients Attenuates insulinemia by increasing




Guar gum High-fat diet supplemented
with 10% guar gum/12 weeks
C57Bl/6 J mice Short-chain fatty acids produced by
colonic fermentation stimulateGLP-1








Anthocianidins (50 µg/mL) and
chlorogenic acid (17.7 µg/mL)
GLUTag cells Inhibitory effect on α-amylase and
α-glucosidase activity, but no effect




Whole plant Water extract
in vitro EC50 113.3 µg/mL
in vivo 100 and 300mg/kg
NCI-H716 cells
Lepr−/− (db/db) mice




















Fruits Water extract (300mg/kg/d
for 28 d)
Diabetic Wistar rats Increases insulinemia and GLP-1 [75]
Plantago indica Fiber-enriched
meals
23 g per meal Healthy young adults Decreases glycemia and insulinemia,




Potato Polyphenolic-rich extracts 1.93
and 3.5% (w/w)/diet
C57BL/6 J mice Reduction in adiposity and
GIP secretion
[73]
DPP-4 = dipeptidyl peptidase-4, GIP = glucose-dependent insulinotropic polypeptide, GLP-1 = glucagon-like peptide-1
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as Inhibitors of Dipeptidyl Peptidase-4
Ríos et al. [34] reviewed the medicinal plants as enhancers of in-
sulin secretion and pancreatic β-cell proliferation and cited differ-
ent plants as possible activators of GLP-1 and GIP or inhibitors of
DPP-4. For example, different inulin-type fructans, such as those
obtained from Cichorium intybus L. (Compositae) and Agave tequi-
lana F.A.C.Weber (Asparagaceae), enhance colon production of
GLP-1, whereas Pterocarpus marsupium Roxb. (Leguminosae) and
Syzygium cumini (L.) Skeels (syn: Eugenia jambolana Lam., Myrta-
ceae) inhibited DPP-4. Indeed, because DPP-4 is an enzyme that
inactivates incretins, its inhibition could increase their level.
Searching for this effect, Kosaraju et al. [76] studied in vitro and
in vivo the potential DPP-4 inhibition of three medicinal plants,
Pterocarpus marsupium, Syzygium cumini, and Gymnema sylvestre
(Retz.) R.Br. ex Sm. (Apocynaceae). Two of them, P. marsupiumRíos JL et al. Modulation of Diabetes… Planta Med 2019; 85: 1–15
▪ Proof copy for correction only. All forms of publication, dup
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tively), whereas G. sylvestre had an IC50 of 773 µg/mL. The three
species had a long duration as enzyme inhibitors, with half-lives
of 462.3, 317.2, and 153.8min, respectively. In conclusion, the
extracts increased GLP-1 levels, and maximum peaks of GLP-1
were appreciated at 2 h for P. marsupium and S. cumini, and at
1.5 h for G. sylvestre. In a parallel analysis with P. marsupium and
S. cumini (200 and 400mg/kg, orally) on streptozotocin-treated
Wistar rats, an increase in GLP-1 levels was observed [77].
Peptides from oat (Avena sativa L., Poaceae), buckwheat (Fago-
pyrum esculentum Moench, Polygonaceae), and highland barley
[Hordeum aegiceras Nees ex Royle, syn: Hordeum vulgare var. trifur-
catum (Schltdl.) Alef., Poaceae] were also studied for their ca-
pacity to inhibit DPP-4. All of them showed in vitro DPP-4 inhib-
itory activity, with IC50 values ranging from 0.13 to 8.15mg/mL.
In total, more than 35 peptides were identified in the tryptic
hydrolysates of oat globulin [78].5
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▶ Fig. 2 Chemical structure of quinovic acid, quinovic acid-3β-O-β-
D-glycopyranoside, and quinovic acid-3β-O-β-D-glucopyranosyl-
(28→ 1)-β-D-glucopyranosyl ester.
▶ Fig. 3 Chemical structure of cyanidin 3,5-diglucoside and
delphinidin 3-rutinoside.
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Koch (Araliaceae) are used in folk medicine for the treatment of
diabetes. To clarify the effect on this illness and its mechanism of
action, Saleem et al. [79] analyzed in vitro the inhibitory effect on
DPP-4 of both plants using a crude extract obtained by macera-
tion with chloroform-methanol (1 :1) during 7 days, and also
tested five isolated compounds. Of them, the crude extract of
H. nepalensis had the best activity (IC50 of 17.2 µg/mL), whereas
the activity of F. cretica was lower (IC50 of 38.1 µg/mL). However,
when the extracts were fractioned and purified, the activity did
not improve. As an example, the ethyl acetate of H. nepalensis
gave an IC50 of 34.4 µg/mL and the n-hexane fraction, an IC50 of
34.2 µg/mL. Regarding the isolated compounds, the inhibitory
activities on DPP-4 did not improve the activity of the original
extracts, so the IC50 values were as follows: quinovic acid
30.7 µM, quinovic acid-3β-O-β-D-glycopyranoside 57.9 µM, qui-
novic acid-3β-O-β-D-glucopyranosyl-(28→ 1)-β-D-glucopyrano-
syl ester 23.5 µM (▶ Fig. 2), and stigmasterol > 100 µM, all of
them from F. cretica. The triterpene lupeol from H. nepalensis was
tested and showed an IC50 of 31.6 µM. Taking together these re-
sults, F. cretica and H. nepalensis could be considered as antidia-
betic agents with potential significant DPP-4 inhibitory activity
[79].
González-Abuín et al. [80] described that grape-seed procyan-
idin extract prevented a decrease in DPP-4 activity and modulated
the gene expression of GLP-1 and its receptor in the hypothala-
mus, inferring that procyanidins can abrogate the effects of the
cafeteria diet on intestinal GLP-1 production and DPP-4 activity.
The administration of the enriched extract to healthy Wistar fe-
male rats induced a plasmatic increase in GLP-1, and a decrease
in glycemia. They also assayed if this inhibition occurred in inner
intestinal tissues close to GLP-1-producing cells, such as the endo-
thelium of the capillaries, and tested the effects of the main com-
pounds, such as catechin, epicatechin, B2 dimer, and gallic acid,
demonstrating that they inhibit DPP-4 activity in endothelial
HUVEC cells in an additive way. They concluded that procyanidins
improve glycemia via GLP-1 secretion caused by the inhibition of
the inner intestinal DPP-4 activity, increasing active GLP-1 levels,
and, in consequence, affecting insulin release [81]. Sulaiman [82]
also investigated the potential role of standardized grape-seed
proanthocyanidin (50mg/kg) on incretin effects as a response to
the glucose load in healthy rats, both oral and i. p., and the results
were compared with the values obtained with sitagliptin (40mg/
kg) and the negative control (vehicle). Both the treated group and
the positive control improved hyperglycemia induced by oral glu-
cose. The mechanism of proanthocyanidin was associated with an
enhancement of the incretin effect of gut peptides, and the au-
thors concluded that the possible action of proanthocyanidin is
via DPP-4 inhibition.
Kozuka et al. [83] tested the juice of aronia berries (Aronia sp.,
Rosaceae) as DPP-4 inhibitors. Enzymatic activity was determined
by fluorometry (excitation 380 nm and emission 440 nm), and
DPP-4 inhibition was performed using L-proline 4-methyl-cou-
maryl-7-amide (Pro-MCA) as the substrate in Tris-HCl (pH 9.0).
The results demonstrated that the juice of aronia berries inhibited
DPP-4 indirectly, increasing GIP and GLP-1. Cyanidin 3,5-digluco-
side (▶ Fig. 3) was identified as the main active principle and6
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searches that identified cyanidin and cyanidin 3-glucoside as
inhibitors of DPP-4, in the present study, the greater potency of
cyanidin 3,5-diglucoside was demonstrated, giving an IC50 of
5.5 µM.
Relevant medicinal plants, their extracts, and concentrations
are summarized in ▶ Table 2, including their effects on DPP-4.Ríos JL et al. Modulation of Diabetes… Planta Med 2019; 85: 1–15
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▶ Table 2 Medicinal plants and natural products as inhibitors of DPP-4.
Plant Extract Concentration Protocol Effects Ref
Aronia sp. Juice fruits No declared In vitro
DPP‑4 + Gly-Pro-MCA
DPP-4 inhibition and
increase in GLP-1 and
GIP levels
[83]
Avena sativa Extracts of seed
proteins
IC50 0.99mg/mL In vitro
DPP‑4 + Gly Pro-pNA and peptide
Inhibition of DPP-4 [78]
Fagonia cretica Aerial parts
CHCl3-MeOH (1 :1)
IC50 38.1 µg/mL In vitro
DPP‑4 + Gly Pro-AMC
Inhibition of DPP-4 [79]
Fagopyrum esculentum Extracts of seed
proteins
IC50 1.98mg/mL In vitro
DPP‑4 + Gly Pro-pNA and peptide
Inhibition of DPP-4 [78]
Gymnema sylvestre Leaves
100% ethanol
IC50 773 µg/mL In vitro
DPP‑4 inhibitor screening assay kit
Inhibition of DPP-4 [76]
Hedera nepalensis Aerial parts IC50 17.2 µg/mL In vitro
DPP‑4 + Gly Pro-AMC
Inhibition of DPP-4 [79]
Hordeum aegiceras Extracts of seed
proteins
IC50 3.91mg/mL In vitro
DPP‑4 + Gly Pro-pNA and peptide








DPP‑4 inhibitor screening assay kit
STZ-treatedWistar rats
DPP-4 inhibition and






In vitro: DPP-4 inhibitor screening
assay kit
In vivo: STZ-treatedWistar rats
DPP-4 inhibition and
increase in GLP-1 levels
[76,77]
Vitis vinifera Grape-seed procyanidin
extract
1mg/kg HealthyWistar rats Increase of GLP-1, and
a decrease in glycemia
[81]
Vitis vinifera Standardized grape-
seed proanthocyanidin
50mg/kg HealthyWistar rats DPP-4 inhibition and
increase in GLP-1 levels
[82]
AMC = amido-4-methylcoumarin, DPP-4 = dipeptidyl peptidase-4, GIP = glucose-dependent insulinotropic polypeptide, GLP-1 = glucagon-like peptide-1,
MCA =methyl-coumaryl-7-amide, pNA = p-nitroanilide, STZ = streptozotocin
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and GIP Secretion
Jafri et al. [84] studied GLP-1 and GIP secretory activity of isolated
compounds from Fagonia cretica in pGIP/neo STC-1 cells, which
secrete both GLP-1 and GIP, and are potentially a very useful mod-
el for studying the secretory responses of both incretin hormones.
Incretins were detected by GLP-1 and GIP ELISA kits. Intracellular
levels of incretin hormones and their gene expression were also
determined by the same protocol. The fresh aerial parts were ex-
tracted with chloroform/methanol (1 :1) and the crude extract, as
well as its n-hexane, ethyl acetate, and aqueous fractions (125 and
250 µg/mL), stimulated both GLP-1 (3- to 55-fold) and GIP (1.6- to
2.2-fold) secretion. Gene expression of GIP was also increased
(6.2- to 12.3-fold). Purified compounds from the ethyl acetate ex-
tract were identified as quinovic acid and its derivatives, 3β-O-β-
D-glycopyranoside and 3β-O-β-D-glucopyranosyl-(28→ 1)-β-D-
glucopyranosyl ester (▶ Fig. 2). These three compounds signifi-
cantly stimulated GLP-1 secretion in pGIP/neo STC-1 cells without
triggering GIP secretion, but 3β-O-β-D-glucopyranosyl-(28→ 1)-
β-D-glucopyranosyl ester was the most active as secretagogue
(at 25 µM it increased GIP secretion 1.6-fold; at 50 µM it increased
the GLP-1 secretory response by 16.9-fold).Ríos JL et al. Modulation of Diabetes… Planta Med 2019; 85: 1–15
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marnieranosides A and B (▶ Fig. 4), isolated from Cynanchummar-
nierianum Rauh (Apocynaceae). These pregnanes (100 µM) in-
creased the release of GLP-1 in STC-1 cells by 130 and 133%, re-
spectively. Isolated marnieranosides showed similar effects as
compound P57, a pregnane analogue responsible for the activity
of Hoodia gordonii (Masson) Sweet ex Decne. (Apocynaceae), used
as a positive control [85]. These same authors isolated five new
pregnane-type steroidal glycosides, menarandrosides A–E,
together with three known compounds, from the aerial parts of
Cynanchum menarandrense Jum. & H.Perrier (Apocynaceae) and
studied them for their potential to stimulate GLP-1 secretion in in-
testinal STC-1 cells. Although the pregnane-rich fraction led to a
2-fold stimulation of GLP-1 secretion vs. blank cells, none of the
pure compounds had any influence, and the fraction enriched in
pregnanes exhibited a significant activity, suggesting a possible
synergistic effect [86].
Spergularia marina (L.) Besser (Caryophyllaceae) is an edible
plant and it is also used as a medicinal plant in Korea for the treat-
ment of diabetes. To analyze this activity, a hydroethanolic extract
(100, 200, and 500 µg/mL) was tested on GLP-1 release from en-
teroendocrine NCI-H716 cells. Treatment of these cells with the
extract increased GLP-1 secretion together with iCa2+ and cAMP
levels in a dose-dependent manner. Transfection of cells with7
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▶ Fig. 4 Chemical structure of marnieranosides A and B.
▶ Fig. 5 Chemical structures of loganic acid, geniposide,
and shanzhiside methylester.
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which demonstrated that S. marina-stimulated GLP-1 secretion in-
volved TGR5 activation and is a possible candidate for antidiabetic
purposes [87].
The roots of Gentiana scabra Bunge (Gentianaceae) are used in
traditional Korean medicine for treatment of T2D, and its proper-
ties were associated with the intestinal bitter taste sensation,
which stimulates GLP-1 secretion. The aqueous extract stimulated
GLP-1 secretion in a dose-dependent manner on human enter-
oendocrine NCI-H716 cells (1–1000 µg/mL, EC50 of 113.3 µg/
mL). In addition, treated Lepr −/− (db/db) mice (100 and 300mg/
kg) decreased glycemia due to the GLP-1 secretion. After chemi-
cal analysis, the authors hypothesized that loganic acid (▶ Fig. 5)
could be the responsible part of GLP-1 secretion [88].
One group of high interest as a source of antidiabetic com-
pounds is procyanidins from grape seed (Vitis vinifera L., Vitaceae).
Since cellular membrane depolarization is determinant for several
nutrient-induced hormone secretions, González-Abuín et al. [89]
employed an in vitro experimental approach to evaluate whether
a procyanidin extract from grape-seeds modulates cellular mem-
brane potential in intestinal endocrine cells (STC-1) and if these
changes influence GLP-1 secretion. They observed that the grape
extract induced opposite effects depending on the dose, depola-
rization at low concentrations (0.05mg/L) and hyperpolarization
at high concentrations (50mg/L). The high concentration was ef-
fective in reducing GLP-1 secretion, even under nutrient-stimulat-
ed conditions [89].
The proanthocyanidins from grape seed also modulate several
parameters involved in metabolic syndrome through changes in
the microbiota and enterohormone secretion. Indeed, it was ob-
served that the ratio of Firmicutes :Bacteroidetes was lower in the
microbiota of rats treated with proanthocyanidins (500mg/kg,
8 d) versus the control, but the extract also increased plasma
GLP-1. For this reason, these kinds of phenolics could be of inter-
est as potential antidiabetics [90].
Other anthocyanins of interest are those present in blackcur-
rant (Ribes nigrum L., Grossulariaceae), which increases GLP-1 se-
cretion in an enteroendocrine L cell line (GLUTag cells). The au-
thors administrated 5mg of fruits/kg, with a content of 1mg
delphinidin 3-rutinoside/kg, and observed that the enriched ex-
tract significantly improved glucose tolerance by stimulating
GLP-1 and insulin secretion, while GLP-1 secretion was stimulated
by delphinidin 3-rutinoside (▶ Fig. 3), but not by its major degra-
dation products, gallic acid and phlorogucinol aldehyde [91].
Black soybean [Glycine max (L.) Merr., Leguminosae] is a type of
soybean with a black seed coat. Previous studies identified antho-
cyanins and procyanidins as the two main types of polyphenols
and described their antidiabetic effects. Qiu et al. [92] demon-
strated that the phenolic-enriched crude extract increased the
concentrations of serum insulin and GLP-1 in streptozotocin-in-
duced diabetic rats after 8 weeks of treatment. However, they
did not identify any specific compound in the extract.
Chlorogenic acids are ubiquitous phenolic compounds present
in different medicinal plants as well as food and beverages, such
as coffee. These kind of phenolics are responsible for different
pharmacological activities, including antidiabetic [64,65]. To
demonstrate the mechanism of these isomers, Tunnicliffe et al.8
▪ Proof copy for correction only. All forms of publication, dup
Dear authors, please note that this pdf is compressed and only used for mail di[93] administered 120mg/kg of chlorogenic acids to male
Sprague-Dawley rats and measured the incretins GLP-1 and GIP.
GLP-1 response was also analyzed using the human colon cell line
NCI-H716. Results showed that the plasma GIP response was
blunted in rats fed chlorogenic acids (▶ Fig. 6), and there were
no changes in GLP-1 secretion in vivo or in vitro, concluding that
treatment with chlorogenic acids modifies GIP concentrationsRíos JL et al. Modulation of Diabetes… Planta Med 2019; 85: 1–15
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▶ Fig. 6 Chemical structures of caffeoylquinic derivatives from
I. batatas leaves [67].
▶ Fig. 7 Chemical structures of rosmarinic acid, berberine, trans-
resveratrol, puerarin, allantoin, and [6]-gingerol.
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of chlorogenic acids and coffee. Chlorogenic acids increase the
production of GLP-1, and this incretin hormone acts on β-cells to
promote the synthesis and activity of the transcription factor IDX-
1, which is crucial for maintaining the responsiveness of β-cells to
an increase in plasma glucose. In addition, chlorogenic acids have
a putative impact on glucose absorption, and this delay may itself
protect β-cells [65]. As mentioned above, the principal com-
pounds studied in this chemical group were 3-caffeoylquinic acid,
3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 4,5-dicaf-
feoylquinic acid, and 3,4,5-tricaffeoylquinic acid (▶ Fig. 6) [67].
Previous papers described Salvia fruticosaMill. (Lamiaceae) as a
possible source of antidiabetic compounds [94]. Azevedo et al.
[95] studied more recently the effects of an infusion from this
species (2.8mg dry extract per mL, “ad libitum”) and its principal
constituent rosmarinic acid (▶ Fig. 7) in drinking water (577 µg/
mL) “ad libitum”. They studied different effects, including those
on GLP-1 using streptozotocin-treated rats. Although the plas-
matic levels of GLP-1 and the number of GLP-1-expressing cells
per cm of villus was smaller in diabetic animals compared with
healthy controls, none of the treatments caused any changes.
The effect of berberine (▶ Fig. 7) on glucose metabolism in di-
abetic rats was studied by Zhang et al. [96], who used two doses
of the compound (120 and 240mg/kg, during 8 weeks) and
found that it significantly decreased fasting blood glucose levels
and, in parallel, increased plasma postprandial GLP-1 levels. In ad-
dition, they verified that the GLP-1 receptor was significantly up-
regulated, suggesting that berberine can improve blood glucose
levels in diabetic rats through a mechanism in which GLP-1 is im-
plicated.
Puerarin (▶ Fig. 7) is a common isoflavone present in different
vegetables, including medicinal plants such as Pueraria montana
var. lobata (Willd.) Sanjappa & Pradeep [syn: Pueraria lobata
(Willd.) Ohwi, Leguminosae]. This compound was evaluated by
Yang et al. [97] for its possible effects on β-cell survival, and the
GLP-1R pathway in db/db diabetic mice and isolated mouse islets
treated with high glucose. They observed that the circulating level
of GLP-1 in mice was unaffected, but puerarin enhanced GLP-1R
expression. The protective effect of puerarin was suppressed by
an antagonist of GLP-1R, concluding that puerarin protects β-cellRíos JL et al. Modulation of Diabetes… Planta Med 2019; 85: 1–15
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Different positive effects of iridoid geniposide (▶ Fig. 5) on in-
sulin secretion and glucose concentration were reported by Guo
et al. [98]. In their experiments with rat INS-1 cells, geniposide
(0.01–100 µM) increased insulin secretion in a concentration-de-
pendent manner, and at 10 µM, it enhanced acute insulin secre-
tion in response to both low and moderately high levels of glu-
cose. The blockade of GLP-1R with an antagonist (exendin,
200 nM) or the knock-down of GLP-1R with shRNA interference
in cells decreased the effect of geniposide (10 µM) on insulin se-
cretion stimulated by glucose (5.5mmol/L). Therefore, the au-
thors concluded that geniposide increases insulin secretion
through GLP-1 receptors in rat INS-1 insulinoma cells.
Shanzhiside methylester (▶ Fig. 5) is an iridoid present in Phlo-
moides rotata (Benth. ex Hook.f.) Mathiesen [Syn: Lamiophlomis
rotata (Benth. ex Hook.f.) Kudô, Lamiaceae]. The anti-allodynia ef-
fect of this monoterpen█monoterpene?█-glycoside is abolished
by the selective GLP-1 receptor antagonist exendin (9–39). This
fact made the authors consider this iridoid as a receptor agonist,
however, it was not studied as a potential antidiabetic compound.
Since it is a geniposide analogue, shanzhiside methylester could
have similar effects on insulin secretion [99].
Crude powder of yam (Dioscorea polystachya Turcz., syn: Dio-
scorea batatas Decne., Discoreaceae), its water extract, and its ac-
tive constituent allantoin (▶ Fig. 7) were analyzed in a rat model of
streptozotocin-induced diabetes. All of them produced a signifi-
cant increase in GLP-1, with allantoin inducing an increment of
162% (2mg/kg, i. v.). The results indicate that yam and allantoin9
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mechanisms and by promoting the release of GLP-1, thereby im-
proving β-cell function, and maintaining normal insulin and glu-
cose levels [100].
Hu et al. [101] studied the effects of ginger (Zingiber officinale
Roscoe, Zingiberaceae) on gastric motility and emptying, abdom-
inal symptoms, and hormones that influence motility in dyspep-
sia, including GLP-1 values, and they observed that the serum
concentration of this incretin was modified. In the same line,
Samad et al. [102] recently reported that GLP-1 mediates the in-
sulinotropic activity of [6]-gingerol (▶ Fig. 7), the major compo-
nent of ginger. Treatment of Leprdb/db type 2 diabetic mice with
this compound increased the activity of glycogen synthase 1 and
enhanced the cell surface presentation of GLUT-4, facilitating glu-
cose disposal in skeletal muscles.
▶ Table 3 compiles the principal compounds from medicinal
plants and their effects on GLP-1 and GIP secretion. It includes ac-
tive compounds, medicinal plants, concentration, experimental
protocols and their effects.Clinical Trials
The number of clinical trials focusing on the effects of medicinal
plant extracts or natural products is quite scarce, and demonstrat-
ed limited effects. Andersson et al. [103] tested an extract (40 g
for 6 weeks) of rose hip fruit (Rosa canina L., Rosaceae) in a ran-
domized, double-blind, crossover study with a total of 31 obese
individuals with normal or impaired glucose tolerance, but the ex-
tract had no effect on incretins.
Although Vallianou et al. [104] cited the antidiabetic potential
of trans-resveratrol (▶ Fig. 7), clinical trials conducted by Brasnyó
et al. [105] did not associate this property with incretins. Indeed,
in a study with 19 patients with T2D, only small changes were de-
tected between the groups treated with resveratrol (5mg × each
day during 4 weeks) versus placebo, but they were not significant.
However, these results must be taken with caution due to the
small number of patients employed.
More promising results were found by Törrönen et al. [106],
who evaluated the effects of different berries on postprandial glu-
cose, insulin, and GLP-1 responses, comparing them with a similar
sucrose load without berries. The study was a randomized, single-
blinded, placebo-controlled, crossover study and enrolled
12 healthy subjects. The participants had two meals on separate
days based on 150 g of a puree made with bilberries (Vaccinium
myrtillus L., Ericaceae), cranberries (Vaccinium macrocarpon Aiton),
blackcurrants (Ribes nigrum), and strawberries [Fragaria × ananas-
sa (Duchesne ex Weston) Duchesne ex Rozier, Rosaceae] and 35 g
of added sucrose (placebo group received an equivalent dose of
sucrose). The glycemia, insulinemia, and GLP-1 concentrations
were monitored during 15 to 120min after taking the meal. Glu-
cose and insulin concentrations were reduced in the group taking
the berry-based meal, although only a modest effect on the GLP-1
response (p = 0.05) was observed.
Regarding worldwide consumed stimulating beverages, such
as coffee and tea, two interesting clinical trials were performed.
Johnston et al. [64] carried out a randomized, crossover study
with 9 healthy fasted volunteers who were given 25 g of glucose10
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caffeinated coffee (equivalent to 2.5mM chlorogenic acid). GIP
secretion decreased, whereas GLP-1 secretion increased (0–
120min, postprandial) after decaffeinated coffee consumption
compared with the control and caffeinated coffee. These results
confirmed the known metabolic effects of caffeine. The gastroin-
testinal hormonal profiles were consistent with delayed intestinal
glucose absorption, suggesting that chlorogenic acid might have
an antagonistic effect on glucose transport, attenuating intestinal
glucose absorption and shifting its absorption to more distal parts
of the intestine. Green tea (Camellia sinensis), which has a similar
phenolic compound profile, was also tested in another clinical trial
with 92 patients with T2D. Thirty-nine of them drank 500mg of
green tea extract, three times a day. After 16 weeks, the green
tea extract caused a significant increase in GLP-1 versus placebo
and significantly improved insulin resistance [107].
More recently, Castro-Acosta et al. [108] published the results
of a randomized, controlled, double-blinded, crossover trial con-
ducted in healthy volunteers to investigate if enriched polyphenol
drinks based on apple [Malus sylvestris (L.) Mill., Rosaceae] and
blackcurrant (Ribes nigrum L.) could affect postprandial blood glu-
cose concentrations. They analyzed different parameters, includ-
ing GIP secretion, in 20 men (age average: 26 years old) and
5 postmenopausal women (age average: 57 years old) who con-
sumed two polyphenol-rich drinks containing fruit extracts or
placebo. Doses administered were 1200mg of apple polyphenols,
or apple polyphenols (600mg) + blackcurrant anthocyanins
(600mg). Postprandial insulin and GIP concentrations were signif-
icantly reduced compared to placebo, but postprandial glycemia
decreased, probably due to the inhibition of GLUT-2 and SGLT1-
mediated intestinal glucose transport.
Finally, in this last year, two clinical trials dealing with dietary
supplements have been published. Boix-Castejón et al. [109] ana-
lyzed a dietary supplement based on a combination of two phe-
nolic extracts from Aloysia citriodora Palau [syn: Lippia citriodora
(Palau) Kunth, Verbenaceae] and Hibiscus sabdariffa L. (Malva-
ceae). They studied 54 overweight subjects in a double-blind,
placebo-controlled intervention, monitoring different vital pa-
rameters during 60 days. Patients taking the phenolic extracts
had an increase in anorexigenic hormones (GLP-1), whereas the
orexigenic hormones (ghrelin) decreased. Zanzer et al. [110]
evaluated the effect of a black pepper-based (Piper nigrum L.,
Piperaceae) beverage containing gallic acid equivalent (20mg) in
a randomized, crossover intervention in 16 healthy subjects
(10 men and 6 women, average age: 26 years old). In this case,
they only noticed some evidence in appetite modulation, but they
did not observe changes in glycemia or gut hormone levels (in-
cluding GLP-1).Future Perspectives and Conclusions
Although this review shows several compounds of interest for the
treatment of T2D that modify glycemia via the modulation of in-
cretin activity, either by direct activation or by repression of its in-
hibitor, there is not a clear structural relationship among them.
The terpenic derivatives of ursane-type structure stand out, with
the glycosylated bidesmosidic derivative being the most activeRíos JL et al. Modulation of Diabetes… Planta Med 2019; 85: 1–15
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▶ Table 3 Natural products as stimulants of GLP-1 and GIP secretion.
Compound Plant Concentration Protocol Effects Ref
Allantoin Dioscorea polystachya 2mg/kg, i. v. STZ-treated Sprague–
Dawley rats
Increases release ofGLP-1 [100]
Berberine Coptis chinensis 120 and 240mg/kg STZ-treated Sprague–
Dawley rats
Increases GLP-1 levels [96]
Chlorogenic acids Coffea arabica 120mg/kg Sprague-Dawley rats
NCI-H716 cells
Increases GIP concentra-
tions and GLP-1 produc-
tion
[120█please check,




Aronia sp. IC50 of 5.5 µM In vitro
DPP‑4 + Gly-Pro-MCA
DPP-4 inhibition and





Ribes nigrum Fruits 5mg/kg
with 1mg/kg delphini-
din 3-rutinoside
GLUTag cells Stimulates GLP-1 and
insulin secretion
[91]
Geniposide Gardenia jasminoides 10 µM INS-1 cells Increases insulin secre-
tion through GLP-1
[98]










100 µM STC-1 cells Increases release ofGLP-1
by 133%
[86]
Procyanidins Vitis vinifera 0.05 and 50mg/L STC-1 cells Suppression of GLP-1
secretion!
[89]
Procyanidins Vitis vinifera 500mg/kg Wistar rats Increases plasma GLP-1 [90]
Puerarin Pueraria montana
var. lobata







Fagonia cretica 25 µM and 50 µM pGIP/neo STC-1 cells







Rosmarinic acid Salvia fruticosa 577 µg/mL, in water
“ad libitum”
STZ-treatedWistar rats No changes in GLP-1 [95]
Shanzhiside
methylester




GLP-1 receptor agonist [99]
DPP-4 = dipeptidyl peptidase-4, GIP = glucose-dependent insulinotropic polypeptide, GLP-1 = glucagon-like peptide-1, GLP-1R = glucagon-like peptide 1
receptor, MCA =methyl-coumaryl-7-amide, STZ = streptozotocin
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phenolic derivatives, cyanidin 3,5-diglucoside, with an IC50 of
5.5 µM, stands out. Considering the compounds that stimulate
GLP-1 secretion, triterpenic derivatives are likewise worth men-
tioning, since they are also bidesmosidic derivatives and marnier-
anosides pregnane derivatives, especially with compounds A and
B (bi- and triglycoside, respectively) being the most active. Even
more interesting are the iridoids (monoterpen█monoterpene?█-
glucosides), such as geniposide and shanzhiside methylester,
which act as GLP-1 receptor agonists. Other compounds, such as
caffeoylquinic acid derivatives, rosmarinic acid, trans-resveratrol,
puerarin, and the alkaloid berberine, could also be of interest.
Among the results obtained experimentally as well as the pre-
vious data referred to in food or clinical trials, it is reasonable to
hypothesize that the inhibition of DPP-4 could be a valid alterna-
tive to deepen these type of studies. However, the limited numberRíos JL et al. Modulation of Diabetes… Planta Med 2019; 85: 1–15
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finitive conclusions cannot be drawn for these compounds. There-
fore, it is recommended to increase the number of trials, putting
emphasis on the importance of unifying the protocols, as well as
increasing the number of patients to follow. Regarding the tests
with experimental animals, it is worth highlighting some com-
pounds whose mechanism is related to the activation of GLP-1R,
especially the iridoid derivatives, which could be valid as leads for
a series of studies with structural analogues. Derivatives of cyani-
din, especially diglycosylated ones, may also be valid, since they
can be an interesting source of DPP-4 inhibitory molecules and
therefore indirectly give rise to the active form of incretins.
In view of the small number of clinical trials, it is only possible
to postulate the complementary use of these medicinal plants
and their active compounds together with standard drugs (e.g.,
metformin) in the treatment of patients diagnosed with T2D or11
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eFirst n.a. Datum 02.05.2019in prediabetes phases. In cases of foods studied as potential anti-
diabetics via incretins, no clear results have been obtained, with
only those which, in practice, can be considered active substances
of medicinal plants being effective, such as guar gum or phenolic
derivatives from different sources. In conclusion, the use of me-
dicinal plants or active compounds should be considered only as
complementary therapy and not as a substitution treatment. On
the other hand, there are some active principles that could be in-
vestigated as potential leads for future treatments of T2D.
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